Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01413191 · ClinicalTrials.gov registry record · Phase 2
Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT01413191: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01413191 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01413191, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
This phase II trial studies how well giving cixutumumab works in treating patients with metastatic melanoma of the eye. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
Interventions
- BIOLOGICAL Cixutumumab
- OTHER Laboratory biomarker analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-08 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01413191
The ClinicalTrials.gov registry entry for NCT01413191 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cixutumumab is the first listed.
NCT01413191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01413191 about?
NCT01413191 is a clinical study titled "Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye". This phase II trial studies how well giving cixutumumab works in treating patients with metastatic melanoma of the eye. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kil...
What is the current status of trial NCT01413191?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2011-08. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01413191?
The interventions under investigation include: Cixutumumab (BIOLOGICAL), Laboratory biomarker analysis (OTHER).
Who is sponsoring clinical trial NCT01413191?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.